Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
NCT ID: NCT00458250
Last Updated: 2008-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
10 participants
INTERVENTIONAL
2006-09-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Some researchers have been performed transplantation from semi-matched (haploidentical) related donors with relatively good results.
Chinese researchers have been performed this kind of transplantation using CAMPATH-1H and their reports indicates good results.
Chinese populations have more homogenous genetic background than Iranians. In this project, we are going to study the feasibility of this method of haploidentical transplantation in Iranian patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the majority of cases, there is no matched related or unrelated donor. Haploidentical hematopoietic stem cell transplantation is a promising alternative for critical cases.
To avoid severe graft versus host disease (GVHD), two types of T cell depletion (TCD) had been used: total TCD and partial TCD.
Total TCD has disadvantages such as increased rate of rejection and relapse, and increased rate of infections due to delayed immune reconstitution.
Partial TCD has been done by in vivo and/or in vitro methods. In haploidentical transplantation, donor partial TCD (ex vivo TCD) without recipient TCD increases the rate of rejection and can not prevent severe GVHD successfully.
In vivo TCD by partial depletion of donor and recipient T cells has been done in haploidentical transplantation with good results (to some extent inferior to full matched transplantations) by using CAMPATH, ATG, etc.
Most of these studies have been performed in Chinese and Japanese populations that have more homogenous genetic background than other populations.
In order to study the feasibility of this kind of transplantation in Iranian patients, we defined a project to perform haploidentical hematopoietic stem cell transplantation by using in vivo CAMPATH-1H.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haploidentical hematopoietic stem cell transplantation
Busulfan
Cyclophosphamide
CAMPATH-1H
Cyclosporin A
Methotrexate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)
* Second remission (CR2) in standard risk patients or CR1 in cases with high-risk features (poor cytogenetic changes or secondary to myelodysplastic syndrome)
* Unavailability of HLA identical related donor or matched unrelated donor.
* Unavailability of other therapeutic intervention that prolongs patient survival.
* Lack of active infection.
* No history of allergy to CAMPATH.
* For adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian..
* Social and intellectual competency of the patient and his/her family to follow medical recommendations.
* The donor must be haploidentical with the recipient: In the order of priority, siblings who have an identical paternal HLA haplotype with the patient, offspring (for female patients that do not have appropriate sibling), and mother.
* Possibly, it is better that the donor and recipient to be of same blood group and sex..
* Possibly, it is better that female donors not to be multiparous.
* Weight greater than or equal to 18 kg.
* Age between 2 and 60 years old.
* For adults: Ability to comprehend the investigational nature of the study and provide informed consent. For minors: Written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.
* Negative two-way WBC crossmatch with the recipient.
Exclusion Criteria
* Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the transplantation procedure unlikely and making informed consent impossible.
* Positive pregnancy test for women of childbearing age.
* HIV positive
* Active infection
* Left ventricular ejection fraction less than 40%
* AST/SGOT greater than 20 x ULN (CTCAE grade IV v3.0)
* Bilirubin greater than 10 x ULN (CTCAE grade IV v3.0)
* Creatinine greater than 6 x ULN (CTCAE grade IV v 3.0)
* Pregnant or lactating
* Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension)
* Sickling hemoglobinopathies including HbSS, HbAS, HbSC
* HBsAg or HIV positive
* Active infection
* CMV positive (for CMV negative recipients)
* Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the BMT treatment unlikely and making informed consent impossible
* Contraindication to general anesthesia.
2 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammadreza Ostadali, MD, Ph.D.
Role: STUDY_DIRECTOR
Hematology-Oncology & BMT Research Center
Ardeshir Ghavamzadeh, MD
Role: PRINCIPAL_INVESTIGATOR
Hematology-Oncology & BMT Research Center
Kamran Alimoghaddam, MD
Role: PRINCIPAL_INVESTIGATOR
Hematology-Oncology & BMT Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology-Oncology & BMT Research Center
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
418-A-1954
Identifier Type: -
Identifier Source: org_study_id